Hematologic malignancies include a broad spectrum of cancers affecting blood, bone marrow, and lymphatic tissues. This session explores advances in disease biology, diagnosis, molecular classification, targeted treatment, immunotherapy, cellular therapy, transplantation, monitoring, and resistance.
Abstract Scope and Participation
Submissions may address leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and other blood cancers. Topics involving molecular diagnostics, targeted agents, immunotherapy, cellular therapy, transplantation, minimal residual disease, and treatment outcomes are welcomed.
[18F]FDG PET/CT has become an integral component in the evaluation of Multiple Myeloma (MM), offering significant advantages in disease detection, staging, treatment response assessment, and…
Multiple myeloma (MM) is one of the most frequent hematological malignancies. Its incidence and mortality rate is globally increasing. Most MM patients experience relapse, which leads to poor…
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Oral and poster slots for original Hematologic Malignancies work, reviewed by the scientific committee.
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Plenary lectures from leading voices shaping Hematologic Malignancies research and practice.
Attend in person in Singapore or join virtually — same programme, same certificate.
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
The Hematologic Malignancies track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Hematologic Malignancies. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Cancer researchers and clinicians, educators and students with an interest in Hematologic Malignancies are all welcome — whether presenting or attending.
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Yes. CIOC 2027 is a hybrid conference — attend the Hematologic Malignancies track in person in Singapore or join live online, with on-demand access afterward.
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.
